Pharmaceutical CRO Industry: A Sector Overview

The pharmaceutical contract research organization (CRO) industry is the outsourced-services layer that sits between drug and biologic sponsors and the clinical trials that generate the data those sponsors submit to regulators.

This guide gives a sector-level view of that industry: how it is structured, why sponsors use it, what services it typically provides, and how sponsors select and govern a CRO relationship. For the regulatory definition of what makes an organization a CRO — the ICH E6(R2) Section 5.2 / 21 CFR 312.52 delegation framework — see the dictionary entry on Contract Research Organization (CRO), which this guide builds on rather than repeats.

Why Pharmaceutical Sponsors Outsource to CROs

Very few pharmaceutical or biotechnology sponsors maintain the full internal capability needed to run a global, multi-site clinical trial end to end. Outsourcing to a CRO is the industry’s standard mechanism for closing that gap, and sponsors typically cite a consistent set of drivers:

• Access to site networks and patient populations. Large CROs maintain relationships with investigator sites across many countries and therapeutic areas, which is faster to access through a CRO than for a sponsor to build independently for a single program.
• Specialized expertise on demand. Biostatistics, regulatory affairs, pharmacovigilance, and data management each require dedicated staff with specific training; a CRO lets a sponsor draw on that expertise without carrying it as permanent headcount, which matters especially for smaller biotech sponsors with a thin internal team.
• Variable-cost flexibility. Clinical development is not a steady-state activity — a sponsor’s trial portfolio expands and contracts by program and phase. Contracting a CRO converts fixed internal capacity into a cost that scales with actual trial volume.
• Speed to activation. An established CRO with existing site relationships, standard operating procedures, and regulatory-affairs staff can often start up a trial faster than a sponsor building the same capability from scratch.
• Global regulatory reach. Multi-regional trials require familiarity with the regulatory expectations of each jurisdiction involved; global CROs maintain that local knowledge across many markets simultaneously.

None of this changes the underlying regulatory principle: under ICH E6(R2) and, for FDA-regulated trials, 21 CFR 312.52, the sponsor retains ultimate responsibility for trial data quality and integrity no matter how much operational work is contracted out. Outsourcing moves the work; it does not move the accountability.

Market Structure: How the CRO Industry Is Segmented

The CRO services market is commonly segmented by scope of service and sponsor type. Market-research estimates (which vary by methodology and firm, and should be treated as directional rather than precise) put the global CRO services market in the tens of billions of dollars annually, with continued growth driven by rising outsourcing rates among both large pharmaceutical companies and smaller biotech sponsors.

• Large, full-service (“Tier I”) CROs — global providers offering turnkey coverage from protocol design through site activation, monitoring, data management, biostatistics, and regulatory submission support. Market-research coverage of this segment names organizations such as IQVIA, ICON, Thermo Fisher/PPD, Syneos Health, Parexel, Fortrea, Labcorp Drug Development, Charles River Laboratories, WuXi AppTec, and Pharmaron as commonly cited examples of scale in this tier — named here as illustrative examples of the segment, not a ranking, endorsement, or exhaustive list.
• Mid-tier and specialty CROs — organizations that compete on depth in a specific therapeutic area (oncology, CNS, rare disease), trial phase (early-phase/Phase I units, for example), or service line (biometrics-only, medical-imaging core labs, central-lab services) rather than end-to-end global scale. Sponsors — particularly mid-sized biotechs — often choose a specialty CRO for a program where deep therapeutic or functional expertise matters more than global breadth.
• Functional Service Provider (FSP) arrangements — not a separate tier of company so much as a different commercial model any CRO (large or specialty) can offer: supplying staff for a single function (e.g., monitoring, data management, medical writing, pharmacovigilance) who work as an extension of the sponsor’s own team and systems, typically across a sponsor’s full portfolio rather than a single trial. See the full-service-vs-FSP comparison in the CRO dictionary entry for how the two commercial models differ operationally.

Sponsor-side sourcing strategy tracks this structure loosely but not rigidly: large pharmaceutical companies with mature clinical operations functions increasingly favor a small number of strategic, preferred-provider CRO relationships (sometimes full-service, sometimes FSP, often a blend) rather than single-trial bidding, while emerging biotech sponsors with little or no internal infrastructure more often need a CRO — frequently full-service — to supply capability the sponsor simply does not have in-house.

Typical CRO Service Lines

A CRO’s scope of work is defined by what a given sponsor contracts it to do, so the same organization can offer a wide range of services and be engaged for only a subset on any one program. Commonly outsourced functions include:

• Clinical operations — site identification, feasibility, and activation; investigator and site contracting; monitoring visits and remote/centralized monitoring; and study management across the trial’s conduct phase.
• Biostatistics and data management — statistical analysis plan development, randomization and blinding, database design, data cleaning and query management, and final statistical analysis — see Clinical Data Management for the standards (CDISC, GCDMP) governing this function.
• Regulatory affairs — preparing and submitting regulatory filings, managing correspondence with authorities, and maintaining the regulatory documentation required to keep a trial in compliance across the jurisdictions it runs in.
• Pharmacovigilance and safety — adverse-event intake and processing, expedited and periodic safety reporting, and signal-detection support — see Pharmacovigilance in Clinical Research for the ICH E2 framework this function operates under.
• Medical writing — protocols, investigator brochures, clinical study reports, and regulatory submission documents.
• Investigational product logistics — packaging, labeling, distribution, and cold-chain management for the investigational product supplied to sites, covered in Clinical Trial Supply Management.
• Quality and compliance support — audit preparation, inspection readiness, and GCP training support for sites and study staff.

The Sponsor-CRO Relationship: Selection, Contracting, and Governance

Beyond the regulatory delegation framework covered in the CRO dictionary entry, the sponsor-CRO relationship has its own commercial and operational lifecycle that a research administrator working on the sponsor side will recognize:

• Selection. Sponsors typically run a request-for-proposal (RFP) process, evaluating candidate CROs on therapeutic-area experience, site network and geographic reach, technology platform (EDC, safety database, eTMF), quality/inspection history, and cost. Bid defense meetings, where shortlisted CROs present their proposed approach directly to the sponsor’s clinical operations team, are common at this stage.
• Contracting. The relationship is formalized through a master services agreement plus study-specific work orders or task orders, which is where the ICH E6(R2)/21 CFR 312.52 written-transfer requirement is operationalized — the contract itemizes exactly which duties move to the CRO and which the sponsor retains.
• Governance and oversight. Once a trial is underway, the sponsor does not disengage — ICH E6(R2) requires active sponsor oversight of CRO-performed work. In practice this takes the form of a vendor/CRO oversight plan, regular study status and quality-metric reviews, co-monitoring or sponsor audit visits, and escalation pathways for quality issues, whether the issue originates with the CRO directly or with a subcontractor the CRO has further engaged (e.g., a central lab or imaging vendor).
• Performance management. Ongoing CRO performance is typically tracked against contracted key performance indicators — site activation timelines, query resolution turnaround, monitoring visit compliance, and safety-reporting timeliness among them — feeding into both the current program’s oversight and future sourcing decisions.

Sector Overview vs. the CRO Definitional Term: How the Two Relate

This guide and the Contract Research Organization (CRO) dictionary entry cover different layers of the same subject. The dictionary term answers a narrower, regulatory question: under ICH E6(R2)/21 CFR 312.52, what specifically makes an organization a CRO for a given trial, what is the sponsor-oversight obligation that comes with that delegation, and how does a full-service engagement differ from a Functional Service Provider arrangement at the contractual level. This guide answers a broader, industry-level question: what does the CRO sector look like as a market, why does it exist as a business model, what functions does it typically perform, and how does a sponsor actually select, contract, and manage a CRO relationship in practice. Readers oriented toward compliance and delegation of duties should start with the dictionary term; readers oriented toward vendor strategy, market landscape, or sourcing decisions will find this guide more directly useful, though the two are meant to be read together.

For readers whose interest is specifically an academic sponsor or institution’s relationship to CRO-like services, see the Academic Research Organization (ARO) discussion within the dictionary entry, and the broader Clinical Research Administration pillar for how CRO relationships fit into the wider clinical research administration lifecycle.

Frequently Asked Questions

What is the difference between a full-service CRO and a specialty CRO?

A full-service CRO offers end-to-end coverage across most or all trial functions — clinical operations, data management, biostatistics, regulatory affairs, safety — typically at global scale. A specialty CRO instead competes on depth in a narrower area: a specific therapeutic area (oncology or CNS, for example), a specific trial phase (early-phase units), or a specific function (biometrics-only or central-lab services). Sponsors choose between them based on whether a program needs broad end-to-end capability or narrow, deep expertise. This is a different axis from the full-service-vs-FSP distinction, which is about commercial engagement model rather than breadth of specialization — see the CRO dictionary entry for that distinction.

Why do pharmaceutical companies use CROs instead of running trials internally?

Most sponsors, including large pharmaceutical companies, do not maintain enough permanent internal capacity to staff every trial in their portfolio at every phase. CROs provide access to established site networks, specialized functional expertise, and variable-cost capacity that scales with a sponsor’s actual trial volume, generally faster than a sponsor could build the same capability internally for a single program.

Does using a CRO reduce a sponsor’s regulatory responsibility?

No. Under ICH E6(R2) and, for FDA-regulated drug and biologic trials, 21 CFR 312.52, a sponsor may transfer performance of specific trial-related duties to a CRO in writing, but ultimate responsibility for the quality and integrity of the trial data always remains with the sponsor. The sponsor is required to actively oversee the CRO’s performance of any delegated duty, not simply contract it out and disengage.

How do sponsors typically select a CRO?

Most sponsors run a request-for-proposal (RFP) process, evaluating candidate CROs on therapeutic-area experience, site network and geographic reach, technology platform, quality and inspection history, and cost, often followed by a bid defense meeting where shortlisted CROs present their proposed approach directly to the sponsor’s clinical operations team.

What services does a CRO typically provide?

Common CRO service lines include clinical operations (site selection, activation, and monitoring), biostatistics and data management, regulatory affairs, pharmacovigilance and safety reporting, medical writing, investigational product logistics, and quality/compliance support. A given CRO engagement may cover all of these or only a specific subset, depending on the contract.

Related CASRAI Resources

• Contract Research Organization (CRO) — the regulatory/definitional entry this guide builds on.
• Clinical Research Associate (CRA) — the CRO-employed monitoring role central to sponsor oversight.
• Clinical Data Management — the data-management function commonly delegated to a CRO.
• Pharmacovigilance in Clinical Research — the safety-reporting function commonly delegated to a CRO.
• Clinical Trial Supply Management — investigational product logistics, another commonly outsourced function.
• Good Clinical Practice (GCP) Certification — the training framework underlying CRO and site staff qualification.
• Clinical Research Administration — this guide’s parent topic cluster.